$NSRX

Nasus Pharma

Share on X

$NSRX

Nasus Pharma

Past 12mo:4mentions1voices

Share on X

All voices4 mentions since Jun 2026calls only

Loading price chart…

Frequently asked

Who mentions $NSRX most on Surfaced?

@investmentguru_ (InvestmentGuru) mentions $NSRX most — 4 mentions in the past 12 months.

When was $NSRX first mentioned on Surfaced?

The earliest tracked mention of $NSRX in the Surfaced archive was on Jun 1, 2026.

How many voices track $NSRX?

1 FinTwit voice has mentioned $NSRX 4 times in the past 12 months.

What kind of voices mention $NSRX most?

$NSRX is mentioned most by Long Research voices on Surfaced.

Recent mentions

4 mentions

@investmentguru_Jun 1, 2026 · 7:29 PM

$NSRX Small-cap biotech. Big potential. Strong Phase 2 data, a differentiated needle-free product, and a clear catalyst path ahead with the IND filing and pivotal study. The opportunity is exciting, but so are the risks. I’m treating this as a speculative position with asymmetric upside—not a core holding. Watch the data. Watch the cash. Watch the execution. Sometimes the biggest winners start with a market cap nobody is paying attention to. Paid promotion Disclaimer: https://t.co/sqUvEMshYU #NSRX #Biotech #SmallCaps #Investing #DYOR 🚀📈

Open on X

@investmentguru_Jun 1, 2026 · 2:30 PM

$NSRX Why are investors paying attention to $NSRX? NS002 isn’t trying to create a new market. It’s trying to improve an existing one. If a patient experiencing anaphylaxis can receive epinephrine: • Faster • Easier • Without a needle Adoption potential becomes very interesting. The pivotal study expected in Q4 2026 will be the key event to watch. #Healthcare #Investing #Biotech Paid promotion, Biotech is always risk reward. Disclaimer: https://t.co/sqUvEMshYU

Open on X

@investmentguru_Jun 1, 2026 · 2:00 PM

$NSRX is one of the more interesting micro-cap biotech stories I’m tracking. Market cap around $60M, but targeting a $2B+ epinephrine market with a needle-free intranasal alternative to EpiPen. Phase 2 data showed: ✅ Faster therapeutic levels ✅ Higher absorption ✅ Strong safety profile The next major catalyst is the planned IND filing in Q3 2026. Paid promotion Advertisement See disclaimer in original post below 👇 #NSRX #Biotech #Stocks

Open on X

@investmentguru_Jun 1, 2026 · 1:29 PM

$NSRX One of the Most Interesting Micro-Cap Biotech Setups Heading Into 2026 Market Cap: ~$60M Nasus Pharma is developing NS002, a needle-free intranasal epinephrine powder designed to compete with EpiPen in the $2B+ anaphylaxis market. Why investors are paying attention: ✅ Phase 2 Data Beat EpiPen • Median time to therapeutic threshold: 1.69 min vs 3.42 min • 91% reached therapeutic levels at 5 min vs 67% for EpiPen • Higher peak concentration and faster absorption • No serious adverse events reported In anaphylaxis, minutes matter. Faster delivery can potentially save lives. (Nasdaq) 📅 Upcoming Catalysts • IND filing expected Q3 2026 • Pivotal study expected Q4 2026 • Potential study readout targeted around Q1 2027 • Additional pipeline programs (NS003, NS004, NS005) expected to enter human studies during H2 2026 (Nasdaq) 💰 Financing Update Many investors focus on the company’s low historical cash balance, but the February private placement raised $15M to advance NS002 and pipeline programs. Management has stated they believe they are funded through the pivotal study and potentially toward NDA submission. (Nasdaq) 🔥 What Makes This Interesting? The needle-free epinephrine market is already validated. Competitor products have shown patients and physicians are willing to adopt alternatives to traditional auto-injectors. If NS002’s superior pharmacokinetic profile continues to hold up in larger studies, the valuation gap between NSRX and larger peers could narrow significantly. (Reddit) Risk • Clinical-stage biotech • No meaningful revenue • Pivotal study execution risk • Binary outcome tied primarily to NS002 investors looking for asymmetric biotech opportunities, NSRX has what many micro-cap biotechs lack: ✔ Differentiated product ✔ Strong Phase 2 data ✔ Large addressable market ✔ Clear regulatory pathway ✔ Multiple catalysts over the next 12 months If management executes and pivotal data confirms Phase 2 results, today’s valuation could look very different. High risk. High reward. Position size accordingly. Paid promotion @TheFlowShark #advertisement Disclaimer: https://t.co/sqUvEMshYU #NSRX #Biotech #Stocks #SmallCaps #Healthcare #Investing

Open on X